Structure Therapeutics Inc. American Depositary Shares Market Cap ($1.45 Billion)
Market Cap & Net Worth: Structure Therapeutics Inc. American Depositary Shares (GPCR)
Structure Therapeutics Inc. American Depositary Shares market cap. Structure Therapeutics Inc. American Depositary Shares (NASDAQ:GPCR) has a market capitalization of $1.45 Billion ($1.45 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7120 globally and #2200 in its home market, demonstrating a -5.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Structure Therapeutics Inc. American Depositary Shares's stock price $20.36 by its total outstanding shares 71309857 (71.31 Million). Also see how efficiently does Structure Therapeutics Inc. American Dep generate cash for how efficiently the company converts equity into cash flow.
Structure Therapeutics Inc. American Depositary Shares Market Cap History (2023–2026)
Structure Therapeutics Inc. American Depositary Shares market cap history from 2023 to 2026. Data shows growth from $2.91 Billion to $1.45 Billion (8.47% CAGR). Check GPCR live share price for real-time trading data and today's change.
Index Memberships
Structure Therapeutics Inc. American Depositary Shares is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.06% | #204 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #795 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.08% | #120 of 263 |
Weight: Structure Therapeutics Inc. American Depositary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Structure Therapeutics Inc. American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Structure Therapeutics Inc. American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Structure Therapeutics Inc. American Dep equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GPCR by Market Capitalization
Companies near Structure Therapeutics Inc. American Depositary Shares in the global market cap rankings as of November 5, 2026. Also see Structure Therapeutics Inc. American Dep (GPCR) total assets for a full breakdown of the balance sheet.
Key companies related to Structure Therapeutics Inc. American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Structure Therapeutics Inc. American Depositary Shares (2023–2026)
Market capitalization of Structure Therapeutics Inc. American Depositary Shares from 2023 to today. Between 2023 and today, Structure Therapeutics Inc. American Depositary Shares's market cap moved from $2.91 Billion to $ 1.45 Billion, with a yearly change of 8.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.45 Billion | -70.73% |
| 2025 | $4.96 Billion | +160.15% |
| 2024 | $1.91 Billion | -34.41% |
| 2023 | $2.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Structure Therapeutics Inc. American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.45 Billion USD |
| MoneyControl | $1.45 Billion USD |
| MarketWatch | $1.45 Billion USD |
| marketcap.company | $1.45 Billion USD |
| Reuters | $1.45 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more